USP researchers develop nanoparticle to accelerate chronic wound healing

Researchers at the University of São Paulo (USP) in Ribeirão Preto, Brazil, have engineered a nanoparticle designed to overcome the multiple barriers that impede the healing of chronic wounds. The technology targets conditions such as diabetic ulcers and pressure sores that can persist for months or years, posing a significant public health challenge. Chronic wounds affect roughly 1 % to 2 % of the population, elevating the risk of infection, amputation, and a marked decline in patients’ quality of life.

The nanoparticle delivers therapeutic agents directly to the wound site, enhancing cellular regeneration and reducing inflammation. By addressing key factors that slow healing—such as impaired blood flow, bacterial colonization, and prolonged inflammatory responses—the system aims to shorten recovery times and improve outcomes for patients who otherwise face prolonged treatment courses. USP’s team plans to advance the formulation through preclinical trials to assess safety and efficacy before moving toward clinical evaluation.

If successful, this innovation could provide a new, targeted approach for clinicians managing chronic wounds, potentially reducing complications and healthcare costs associated with long‑term wound care. The development underscores the importance of continued research into advanced biomaterials for improving patient outcomes in wound management.